- Built to Serve: The Day That Reminds Us Why We Chose Dentistry
- Journalists Catch You Up on Fauci Hearing, Peptides, and Kids’ Caffeine Consumption
- CMS finalizes 2.3% hospital pay bump, mandatory joint replacement model: 9 things to know
- How ambulatory shifts are reshaping perioperative strategy
- Cyclosporiasis cases top 18,000: 3 updates
- How Allegheny Health Network Strengthened its Foundation for IV Compounding Safety with Automation and Standardization¹
- Health plan customer service reps have AI in their ear
- Centene’s buyouts could have a $315M+ price tag for the rest of the year
- Medicare pay cut sparks specialty battle over skin cancer care
- Cardiovascular Institute of New England provides notice of data incident
- CMS locks in 2.3% inpatient hospital base pay increase, nudges back CJR-X Model start date
- Why autonomy — not just capital — is winning over cardiologists
- The $36 vs. $95 problem: How RVU negotiations are skewing physician pay
- Mississippi hospital board member, former CEO remembered as advocate for rural communities
- Pennsylvania SUD treatment locator reaches 146K users
- Top 10 dental, DSO stories in July
- Ohio youth treatment facility faces scrutiny over reported abuse: 8 notes
- What dental leaders told us in July
- Urban hospital closures and net change, by state
- Nebraska launches dashboard tracking rural health funds
- ADSO sues Colorado Dental Board over practice ownership rule
- New patient acquisition is the top growth driver for dental practices: Report
- 20 new behavioral health projects to know
- Nurses, patients protest North Star Health Alliance ASC closure
- No Surprises Act under attack by payers: 8 things to know
- Dental staffing wages up 23% since 2021: ADA
- AtlantiCare appoints anesthesiology, gastroenterology physician leaders
- Consumer dental spending up 24% over 10 years: 5 stats to know
- Baylor Scott & White joint venture expands outpatient behavioral health services
- 5 DSOs making headlines
- VA to explore GLP-1 treatment for alcohol use disorder: 4 notes
- A $5B wave of M&A hits the ASC industry
- FTC Sues Hims & Hers Over Health Privacy And Billing Practices
- 145 physician medical groups led all healthcare M&A sectors in Q1
- 10 new ASCs in July
- Healthcare exec, telemedicine company owner sentenced for $35M DME fraud scheme
- Amylyx demystifies post-bariatric hypoglycemia with patient education website
- What Dad Eats Before Conception May Influence Baby's Health
- Family History Plays Role In Genetic Risk For Breast Cancer, Researchers Find
- A look at employers' attitudes toward ICHRAs
- Revised 340B Rebate Model Pilot Program moves forward, despite provider pushback
- Function Health lands $450M in growth financing to scale tech-enabled preventive health
- Daiichi Sankyo flags accounting error, as shares tank despite revenue beat
- AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
- Op-ed: Hospitals on the edge, a time for CMS to do no harm
- Daily Routine Key To Good Health, Study Says
- Alignment Healthcare boasts 32% revenue jump in Q2, lifts 2026 outlook
- Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
- Psilocybin Therapy Helps Ease Veterans' Severe PTSD, Pilot Study Finds
- Newsom Reverses On Long-Sought Paid Leave Benefit For California Teachers
- Nicotine Levels Are Rising Among Teens Who Vape, New Study Warns
- The Newest Federally Recognized Tribe Wants Better Healthcare. It May Be On Its Own.
- They Worked To Protect Public Health. Now They Want the Public’s Votes.
- 27 new behavioral health study findings to know
- 21 state behavioral health policy updates
- What will fuel the next wave of DSO growth
- Dentists’ biggest staffing headaches
- Shionogi makes the call on COVID pill Xocova TV spot
- Psilocybin-assisted therapy reduced PTSD symptoms: 3 notes
- Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod
- Psychedelics, peptides and GLP-1s
- How 'physician-led' care team models tackle primary care's workforce problem
- How 7 systems divert behavioral health patients from the ED
- WellSpan Health, Hippocratic AI ink ‘multi-year’ partnership with plans to co-develop clinical AI agents
- Kaiser faces complaint over automated behavioral health triage system
- Free research hub Nila aims to demystify menopause, other hormone conditions
- Scientists Defend Fauci's Pandemic Work As Senate Hearing Turns Bitter
- Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
- Study Questions Effectiveness of Antihistamines in Easing Eczema
- Vaping Is Likely Reshaping The Future Of Cancer In The US, Study Argues
- Weekly Rundown: Counsel Health rolls out white label AI care platform; Community Health Network launches MyChart AI assistant
- New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
- Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
- Waystar boosts 2026 outlook as AI-powered RCM solutions gain traction with providers
- YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort
- Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
- Sugar Consumption Early In Life Linked To Increased Dementia Risk, World War II-Era Data Show
- Work Stress Harming Middle-Age Sleep, Study Says
- RFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
- Hospice's Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Cell Phone Ownership Linked To Lower Reading Skills In Elementary Students
- Listen to the Latest ‘KFF Health News Minute’
- Medicaid Insurers’ Contracts on the Line in Tight Governor’s Race
- Abortion Drug Law in Louisiana Heightens Hemorrhage Risk for Pregnant Patients
- Teladoc Health trims 2026 revenue forecast amid challenges with BetterHelp insurance shift
- Cigna CEO: Express Scripts seeing 'significant early interest' from clients for new rebate-free PBM model
- Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler
- Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
- FTC sues Hims & Hers over data privacy, billing practices
- CMS' proposed 340B reimbursement cut—who wins, and who loses?
- Virtual care helps patients improve their gambling disorder symptoms, Birches Health finds
- Case Western Reserve University launches next-generation healthcare leadership program
- Lilly, Resilience commit $750M to boost US diabetes, obesity med production
- CMS ending Medicare Part D subsidy program
- Red Cross Declares Rare National Blood Supply Crisis Amid Summer Shortfall
- Not Just Pregnancy Fatigue: Could It Be Sleep Apnea?
- More Women Drinking During Pregnancy
- Wellstar Health System lays off 761 corporate, administrative staff
- Biogen flips '26 guidance from expected decline to sales increase
- Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge
- Talking To Your Baby? Eye Contact Is Key To Language Development, Experiment Shows
- Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026
- Leapfrog launches expanded ASC public reporting program
- Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead
- DoorDash, GrubHub Delivering Junk Food To 1 In 4 Teens During School Hours
- Uninsured but Undaunted, a Surgical Patient Searched the Globe for a Deal
- Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare
- Hospice’s Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Humana plans more market exits for 2027, CFO says
- PMCPA sanctions melatonin drugmaker over misleading information
- CG Life embraces next-gen era in merger with AI-native agency The Considered+AI
- How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval
- Fifth Death Reported In NYC Legionnaires' Disease Outbreak
- Many Young Adults Aren't Ready To Manage Their Own Healthcare, Poll Finds
- Can A Daily Multivitamin Help You Stay Active As You Age?
- Stellarus launches AI-powered health plan customer service representative copilot
- Prebiotic Soda Health Claims Questioned In New Nutrition Study
- Family-Based Childhood Obesity Program Helps Kids Cut Weight, Become Healthier
- To Afford Aging In Place, Older Adults Turn To 'Golden Girls' Housing
- Breakfast Can Help Teens Make Better Food Choices Throughout Their Day, Study Says
- Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California
- FDA Panel Backs Two Peptides For Compounding, Rejects One
- How Accurate Are Photo-Based Calorie Apps? 4 Are Put To The Test
- Popular School Cafeteria Meals Need An Update To Meet Healthy Food Standards, Researchers Say
- Ovarian Syndrome Quadruples Heart Disease Risk In Women, Major Study Concludes
- Weed-Killing Chemical, Glyphosate, Linked To Premature Births In Humans, Study Says
- 'The Child Is Terrified': Doctors On Front Lines Of Measles Comeback Speak Out
- 'Yo-yo' Weight Loss Linked To Decline In Muscle Mass
- FDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatments
- Frequent Marijuana Use Linked To Higher Stress Hormone Levels
- Back Pain? Try Swimming, Study Says
- Ozempic Cuts Down Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
- Money Problems Might Make Your Brain Old Before Its Time, Study Suggests
- Black MS Patients Dying Younger Than White Ones, Study Finds
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
- Remarks to the Small Business Capital Formation Advisory Committee
- Statement on Regulation E-Delivery
- Paper Taper: Statement on Proposed Regulation E-Delivery
- Statement on Proposed Regulation E-Delivery
- Senate HELP committee advances nominees for CDC director, HHS preparedness head
- Remarks before the American-Hellenic Chamber of Commerce
- Remarks at the Society for Corporate Governance Conference
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- Statement on the 2026 Regulatory Agenda
Michigan healthcare freedom community forum
People across the country are reporting illnesses after microdosing psilocybin with mushroom products from Diamond Shruumz of California. Microdosing involves taking very small doses of psychedelics in specially selected mushroom varieties, typically 10% to 20% of recreational doses.
The Michigan Department of Health and Human Services is warning Michigan's trend setters not to eat Diamond-Shruumz products. The U.S. FDA and Centers for Disease Control and Prevention are investigating illnesses associated with Diamond Shruumz-brand microdosing chocolate bars, infused cones, or microdose and macrodose gummies. The products are labeled as having a blend of mushroom varieties like Reishi and Lion's Mane. Their active ingredient, psilocybin is classified as a hallucinogen. Psilocybin used to cause all kinds of strange behaviors 50 years ago when it was a popular street drug.
Psilocybin mushrooms have been decriminalized in Ann Arbor and Detroit.
MDHHS alerting Michigan residents not to eat Diamond Shruumz-brand chocolate bars, cones and gummies during ongoing FDA investigation
By Lynn Sutfin - June 18, 2024LANSING, Mich.-The Michigan Department of Health and Human Services (MDHHS) and the Food and Drug Administration (FDA) are urging Michigan residents not to eat, sell or serve any flavor of Diamond Shruumz-brand Microdosing Chocolate Bars, Infused Cones or Micro Dose and Macro Dose gummies, and instead throw them away. The products are labeled as containing a proprietary blend of mushrooms such as reishi and lion’s mane.
“People in multiple states have become ill after eating these products, reporting a variety of severe symptoms,” said Dr. Natasha Bagdasarian, chief medical executive. “As these products look similar to candy, we urge parents and caregivers to consider discussing this information with their teens even though they are intended for individuals 18 and older. We are advising that everyone avoid these products.”
As of Friday, June 7, the FDA and Centers for Disease Control and Prevention (CDC), in collaboration with America’s Poison Centers and state and local partners, are investigating a series of illnesses associated with eating Diamond Shruumz-brand products. The FDA is working to determine the cause of these illnesses.
A total of 26 illnesses have been reported from 16 states, including Alabama, Arizona, California, Indiana, Kentucky, Maryland, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, Pennsylvania, South Carolina and Tennessee. To date, there are no reported cases in Michigan.
Of those who became ill, 25 people reported seeking medical care, with 16 being hospitalized. No deaths have been reported. People who became ill from eating Diamond Shruumz-brand products reported a variety of severe symptoms including seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper/hypotension, nausea and vomiting.
Diamond Shruumz-brand products can be purchased online or at a variety of retail locations nationwide, including smoke/vape shops or places that sell hemp-derived or CBD products.
Retailers should not sell or distribute any of these products. Instead, hold these products until further direction is given by the FDA.
Those who become ill after consuming these products should seek medical treatment. They can also call the Poison Help Line at 800-222-1222 to report symptoms and seek information. Callers should let Poison Control know they have recently consumed a Diamond Shruumz-brand chocolate bars, cone or gummies.
Health care providers should report these illnesses to their local health department or the Poison Help Line at 800-222-1222.
MDHHS will continue to monitor incoming information from FDA. Consumers and health care providers can monitor updates about this investigation at Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) | FDA.
Physicians or residents with questions or concerns can contact MDHHS by calling 844-464-7327 or emailing mdhhs-eht@michigan.gov.
FDA is now investigating one death associated with these Diamond Shruumz microdose products, and it is now believed that the toxic agent which caused these sicknesses is muscimol not psilocybin:
https://www.upi.com/Health_News/2024/07/03/Diamond-Shruumz-death/5371719992921/
FDA probing death potentially linked to recalled microdosing candies
By Darryl Coote - July 3, 2024July 3 (UPI) -- Federal food safety officials are investigating a potential death linked to ingesting recalled microdosing chocolates and candies that have sickened dozens of people across the United States.
All Diamond Shruumz-brand chocolates and gummies were recalled late last month over the products containing toxic levels of muscimol, a chemical found in some mushrooms that can cause seizures, involuntary muscle contractions and a loss of consciousness, among other issues.
At least 48 illnesses linked to the edibles have been reported in 24 states as of Monday, the Food and Drug Administration said in an update to the recall on Tuesday.
Twenty-seven of the patients have been hospitalized, it said, adding that there is one potentially associated death under investigation.
American Poison Centers in a statement added that it has received 82 reports of exposure associated with the Diamond Shruumz products, including 48 cases of severe illness, of which all but two sought medical attention.
The FDA said those who became ill after eating Diamond Shruumz-brand products reported a variety of severe symptoms, including seizures, central nervous system depression, agitation, abnormal heart rates, nausea and vomiting.
Diamond Shruumz is instructing its customers to not eat their products amid the investigation. It said in a statment on its website that those who became ill from eating their products had consumed "the entire chocolate bar and some products containing higher levels of muscimol than normal."
The FDA is also recommending not to eat, sell or serve any flavor of Diamond Shruumz-brand chocolate bars, cones or gummies. Those in possession of the recalled products are being instructed to either discard them or return them to the company for a refund.
The products affected by the recall were sold online as well as at retail stores that sell such products, including smoke and vape shops.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.





















